Becker Muscular Dystrophy (BMD)

Utrophin Modulator SMT C1100 To Be Tested in DMD Patients

Summit PLC, a biotechnology company based in Abingdon, United Kingdom, has announced it has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and Ethics Review Committee to begin testing its experimental drug SMT C1100 in children with Duchenne muscular dystrophy (DMD).

BMD, IBM: Preliminary Findings in Follistatin Gene Transfer Study Promising

Preliminary results from a trial to test the safety of injecting follistatin genes into the thigh muscles of adults with Becker muscular dystrophy (BMD)or sporadic (nongenetic) inclusion-body myositis (sIBM) suggest that the experimental therapeutic approach is safe in both types of patients

Nitric Oxide Drug Trial in Becker MD Now Open

A new drug trial is now under way at Cedars-Sinai Medical Center in Los Angeles for men with Becker muscular dystrophy (BMD) who meet study criteria.

New Tadalafil Trial in Becker MD Now Open

A new trial of tadalafil (Cialis), a drug that dilates blood vessels, is now under way at Cedars-Sinai Medical Center in Los Angeles for men with Becker muscular dystrophy (BMD) who meet study criteria.

2013 BMD Conference Covered Research, Medical Care and Daily Life

The 2013 MDA-supported Becker Muscular Dystrophy Conference, held Aug. 24 in Baltimore and co-hosted by MDA and Johns Hopkins Medicine, was "high-energy" with "phenomenal" presenters, says Annie Kennedy, MDA's senior vice president of advocacy, who attended and helped organize the meeting.

Some 130 people attended in person and many more, including some from outside the United States, attended online.

DMD: Summit Granted Patents for Utrophin Booster

Summit PLC, a biotechnology company based in Abingdon, United Kingdom, has announced it now has two U.S. patents for its experimental drug SMT C1100 for Duchenne muscular dystrophy (DMD).

The patents will provide commercial protection to the company as it continues the further development of this drug. However, the drug will not become available to patients until it receives approval from regulatory agencies.

Becker MD Conference Can Be Attended Online Aug. 24

MDA and John Hopkins Medicine will present the 2013 national Becker Muscular Dystrophy Conference Saturday, August 24, in Baltimore. Free to all participants with BMD and their family and friends, the conference can be attended in person or online.

Nationwide Children’s Podcast Explores Therapy Development for DMD

In a July 2013 podcast from Nationwide Children’s Hospital in Columbus, Ohio, longtime MDA grantee Jeffrey Chamberlain discusses recent advances in the development of gene therapy (gene transfer) and stem cell therapy (transplantation) for Duchenne muscular dystrophy (DMD), the results of which may apply to other types of muscular dy

DMD/BMD — Lynn Megeney, Ph.D.

Lynn Megeney, senior scientist at the Sprott Centre for Stem Cell Research, Ottawa Hospital Research Institute in Ottawa, Ontario, Canada, was awarded an MDA research grant totaling $300,000 over a period of three years to study how muscle stem cells are controlled.

Pages